Sign In
Buy ADAG
$3.75
+0.0200 (+0.536%)
At Close: Jul 31, 2026
- Data from first tranche of MSS CRC patients treated with ADG126 10 mg/kg every three weeks (Q3W) in dose expansion showed clinical benefit including confirmed responses at higher, more frequent and
- Interim results in MSS CRC suggest that SAFEbody precision masking technology enables a new standard for anti-CTLA-4 therapy at higher, more frequent and repeat doses by overcoming longtime safety-
Adagene Presents Data Demonstrating the Best-in-Class Therapeutic Index for Masked Anti-CTLA-4 SAFEbody® ADG126 at SITC 2023
12:00pm, Friday, 03'rd Nov 2023
- MSS CRC case examples reinforce optimal dosing regimen in ongoing phase 2 dose expansion, with a confirmed partial response at ADG126 10 mg/kg every three weeks plus pembrolizumab –
- Data reinforces mechanism of action and selection of 10 mg/kg every three weeks repeat dosing regimen with pembrolizumab in ongoing MSS CRC dose expansion cohort –
Is Adagene (ADAG) Outperforming Other Medical Stocks This Year?
11:17am, Wednesday, 27'th Sep 2023
Here is how Adagene Inc. Sponsored ADR (ADAG) and AN2 Therapeutics, Inc. (ANTX) have performed compared to their sector so far this year.
Are Medical Stocks Lagging Adagene (ADAG) This Year?
11:16am, Thursday, 07'th Sep 2023
Here is how Adagene Inc. Sponsored ADR (ADAG) and Alcon (ALC) have performed compared to their sector so far this year.
Adagene to Present at Investor and Scientific Conferences in September
06:00am, Thursday, 07'th Sep 2023
– Adagene's CEO, Dr. Peter Luo, participating in SITC webinar on September 22 focused on essential role of Treg depletion for anti-CTLA-4 therapies –
Adagene Reports Six Month Financial Results for 2023 and Provides Corporate Update
07:32am, Thursday, 31'st Aug 2023
- Best-in-class anti-CTLA-4 candidates designed for more than 30-fold increase in therapeutic index, addressing patient populations where CTLA-4-mediated Treg depletion is essential for efficacy –
Is Adagene (ADAG) Stock Outpacing Its Medical Peers This Year?
10:46am, Thursday, 25'th May 2023
Here is how Adagene Inc. Sponsored ADR (ADAG) and The Cooper Companies (COO) have performed compared to their sector so far this year.
Adagene to Present at the Biotech Showcase™ 2023 in San Francisco on January 9
04:01pm, Thursday, 05'th Jan 2023
SAN DIEGO and SUZHOU, China, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of antibody-based therapies, today anno
Adagene to Participate in Investor Conferences in May and June
07:00am, Thursday, 12'th May 2022
SAN DIEGO and SUZHOU, China, May 12, 2022 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today
Adagene (ADAG) Gets FDA Nod for Cancer Study on ADG126 Combo
12:02pm, Thursday, 17'th Mar 2022
The FDA grants clearance to Adagene (ADAG) to begin clinical studies on its anti-CTLA-4 mAb, ADG126 in combination with pembrolizumab to treat advanced/metastatic solid tumors.
Adagene Shares Pop After FDA Clears Phase 1b/2 Trial For ADG126/Keytruda Combo Therapy In Solid Tumors
10:07am, Wednesday, 16'th Mar 2022
The FDA has cleared Adagene Inc's (NASDAQ: ADAG) Phase 1b/2 clinical trial of its anti-CTLA-4 monoclonal antibody (mAb), ADG126, in combination with Merck & Co Inc's (NYSE: MRK) Keytruda (pembrol
Investors Hoping for News at Cancer Meeting That Will Boost Share Prices
05:30pm, Thursday, 10'th Mar 2022
Given that developing biotechnology companies are more susceptible to swings in stock price than established ones, investors might want to keep an eye on happenings at next month's American Associatio
Adagene Announces Four Poster Presentations on Robust Preclinical Pipeline of Antibody-Based Therapeutics at Upcoming American Association for Cancer Research (AACR) Annual Meeting
10:28pm, Tuesday, 08'th Mar 2022 GlobeNewswire
- New IND-enabling programs reinforce commitment to build a deep, broad and differentiated pipeline that transforms cancer immunotherapy leveraging company’s AI-powered platform -
